摘要
目的 探讨牛蒡根茯苓方纳米制剂对马兜铃酸诱导的斑马鱼肾功能损伤模型的保护作用。方法采用水溶给予90 nmol/L马兜铃酸建立斑马鱼肾功能损伤模型。设置正常对照组、模型对照组、阳性对照组（地塞米松，9.81μg/mL）及牛蒡根茯苓方纳米制剂低、中、高剂量组（500，1000，2000 μg/mL）。通过测定斑马鱼全身荧光强度评价肾小球滤过功能，并检测肌酐（Cr）含量评估肾脏排泄功能。结果 与正常对照组相比，模型对照组斑马鱼全身荧光强度与肌酐含量均极显著升高（P<0.001）。经牛蒡根茯苓方纳米制剂干预后，各剂量组斑马鱼全身荧光强度显著降低（500 μg/mL组 P<0.05，1000、2000 μg/mL组 P<0.001），肌酐含量亦呈剂量依赖性极显著降低（P<0.001）。结论 牛蒡根茯苓方纳米制剂可通过促进肾小球滤过和降低肌酐含量，有效改善马兜铃酸诱导的斑马鱼肾功能损伤，具备良好的肾保护应用潜力。
关键词： 中药复方纳米制剂；牛蒡根茯苓方；肾损伤；动物实验
Abstract
Objective To investigate the protective effect of Burdock Root and Poria Cocos Compound Nanopreparation on aristolochic acid-induced renal function injury in a zebrafish model. Methods A renal injury model was established by exposing zebrafish to 90 nmol/L aristolochic acid in water. The zebrafish were randomly divided into a normal control group, a model control group, a positive control group (dexamethasone, 9.81 μg/mL), and low-, medium-, and high-dose groups of the Burdock Root and Poria Cocos Compound Nanopreparation (500, 1000, 2000 μg/mL). Glomerular filtration function was evaluated by measuring the systemic fluorescence intensity of the zebrafish, and renal excretory function was assessed by detecting creatinine (Cr) content. Results Compared with the normal control group, the model control group showed a highly significant increase in both systemic fluorescence intensity and creatinine content (P<0.001). After intervention with the Burdock Root and Poria Cocos Compound Nanopreparation, all dose groups exhibited a significant reduction in systemic fluorescence intensity (500 μg/mL group, P<0.05; 1000 and 2000 μg/mL groups, P<0.001). Creatinine content also showed a dose-dependent and highly significant decrease (P<0.001). Conclusion The Burdock Root and Poria Cocos Compound Nanopreparation can effectively ameliorate aristolochic acid-induced renal function injury in zebrafish by promoting glomerular filtration and reducing creatinine content, demonstrating good potential for renal protection applications.
Key words： Traditional Chinese medicine compound nanopreparation; Burdock Root and Poria Cocos Formula; Renal injury; Animal experimentation
参考文献 References
[1] Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: A review [J]. JAMA, 2019, 322(13): 1294-1304.
[2] Wang F, Yang C, Long J, et al. Executive summary for the 2015 annual data report of the china kidney disease network (ck-net) [J]. Kidney Int, 2019, 95(3): 501-505.
[3] Diseases GBD, Injuries C. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: A systematic analysis for the global burden of disease study 2019 [J]. Lancet, 2020, 396(10258): 1204-1222.
[4] Lv JC, Zhang LX. Prevalence and disease burden of chronic kidney disease [J]. Adv Exp Med Biol, 2019, 1165: 3-15.
[5] 姬满山, 周竹. 慢性肾脏病的中西医治疗进展 [J]. 云南医药, 2025, 46(05): 86-89.
[6] 黄露艳. 肾损伤的中医认识与治疗 [J]. 四川中医, 2020, 38(04): 44-47.
[7] Teja PK, Mithiya J, Kate AS, et al. Herbal nanomedicines: Recent advancements, challenges, opportunities and regulatory overview [J]. Phytomedicine, 2022, 96: 153890.
[8] Liu M, Chen X, Chen H, et al. Nanotechnology-based drug delivery system for anticancer active ingredients from traditional chinese medicines: A review [J]. Am J Chin Med, 2022, 50(8): 2011-2032.
[9] Zhang YB, Wang JF, Wang MX, et al. Nano-based drug delivery systems for active ingredients from traditional chinese medicine: Harnessing the power of nanotechnology [J]. Front Pharmacol, 2024, 15: 1405252.
[10] 何语涵, 李育霈, 苏白海. 纳米药物治疗慢性肾脏病的研究进展 [J]. 临床肾脏病杂志, 2025, 25(06): 516-520.
[11] Huang Y, Ning X, Ahrari S, et al. Physiological principles underlying the kidney targeting of renal nanomedicines [J]. Nat Rev Nephrol, 2024, 20(6): 354-370.
[12] Cosyns JP. Aristolochic acid and 'chinese herbs nephropathy': A review of the evidence to date [J]. Drug Saf, 2003, 26(1): 33-48.
[13] 孙梦豫, 邓清月, 孙澜彬, 等. 数据挖掘《中国药典》2020年版肾病相关中药成方制剂的核心药对及其作用靶点预测 [J]. 中草药, 2025, 56(01): 191-202.
[14] Yosri N, Alsharif SM, Xiao J, et al. Arctium lappa (burdock): Insights from ethnopharmacology potential, chemical constituents, clinical studies, pharmacological utility and nanomedicine [J]. Biomed Pharmacother, 2023, 158: 114104.
[15] Nie A, Chao Y, Zhang X, et al. Phytochemistry and pharmacological activities of wolfiporia cocos (f.A. Wolf) ryvarden & gilb [J]. Front Pharmacol, 2020, 11: 505249.
[16] Feng YL, Cao G, Chen DQ, et al. Microbiome-metabolomics reveals gut microbiota associated with glycine-conjugated metabolites and polyamine metabolism in chronic kidney disease [J]. Cell Mol Life Sci, 2019, 76(24): 4961-4978.
[17] Zhang J, Wu C, Gao L, et al. Astragaloside iv derived from astragalus membranaceus: A research review on the pharmacological effects [J]. Adv Pharmacol, 2020, 87: 89-112.
[18] 吕冬菊, 黄东明, 段伟静. 黄芪甲苷调控hmgb1/nf-κb通路对脓毒症大鼠巨噬细胞极化和急性肾损伤的机制研究 [J]. 中国煤炭工业医学杂志, 2025, 28(01): 1-7.
[19] 孙健, 樊卫平, 郎捷. 黄芪总皂苷对免疫球蛋白 a 肾病大鼠肾损伤的保护作用及其对 tgf-β/smad 信号通路的影响研究 [J]. 中华中医药学刊: 1-13.
[20] Rios JL. Chemical constituents and pharmacological properties of poria cocos [J]. Planta Med, 2011, 77(7): 681-691.
[21] Suryantoro SD, Iwanoski G, Sutanto H, et al. Resveratrol in renal health: Bridging therapeutic gaps from acute kidney injury to chronic disease prevention [J]. J Physiol, 2024, 602(10): 2165-2167.